The tumor sample was subjected to a multikinase® panel and revealed HER-2 (human epidermal growth factor receptor 2) (65%) and EGFR1 (epidermal growth factor receptor-1) (50%) overexpression, VEGFR-2 (vascular endothelial growth factor receptor 2) (35%), PDGFR-beta (platelet-derived growth factor receptor beta) (15%), and mild c-KIT expression (15%). Here, ERBB2 is linked to neoplasm.